Mobile Menu

  • AboutUs_Normal-24 The EyeCRO Approach
    • About Us
    • Careers
    • Location
    • Partners
  • MiDrops MiDROPS™
  • InVivo Models
    • Allergic Conjunctivitis
    • Corneal Sensitivity
    • Corneal Wound Healing
    • Diabetic Keratopathy
    • Dry Eye Disease
    • Endotoxin induced Uveitis
    • Experimental Autoimmune Uveitis
    • Geographic Atrophy
    • Inherited Retinal Degenerations
    • Ischemia Reperfusion Injury
    • Laser-induced Choroidal Neovascularization
    • Light Damaged
    • Optic Nerve Crush
    • Oxygen Induced Retinopathy
    • Retinal Detachment
    • Retinal Vein Occlusion
    • Rotenone-induced Optic Neuropathy
    • STZ-induced Diabetic Retinopathy
    • VEGF-induced permeability
  • InVitro Capabilities
    • Biochemistry
    • Bioanalytical Detection
    • GLP Toxicology and PK Studies
    • Histology
    • Ophthalmic Imaging and Physiology
  • News News
  • ContactUs Contact Us
  • Menu
  • Skip to primary navigation
  • Skip to main content

EyeCRO Logo

  • AboutUs_Normal-24 The EyeCRO Approach
    • About Us
    • Careers
    • Location
    • Partners
  • MiDrops MiDROPS™
  • InVivo Models
    • Allergic Conjunctivitis
    • Corneal Sensitivity
    • Corneal Wound Healing
    • Diabetic Keratopathy
    • Dry Eye Disease
    • Endotoxin induced Uveitis
    • Experimental Autoimmune Uveitis
    • Geographic Atrophy
    • Inherited Retinal Degenerations
    • Ischemia Reperfusion Injury
    • Laser-induced Choroidal Neovascularization
    • Light Damaged
    • Optic Nerve Crush
    • Oxygen Induced Retinopathy
    • Retinal Detachment
    • Retinal Vein Occlusion
    • Rotenone-induced Optic Neuropathy
    • STZ-induced Diabetic Retinopathy
    • VEGF-induced permeability
  • InVitro Capabilities
    • Biochemistry
    • Bioanalytical Detection
    • GLP Toxicology and PK Studies
    • Histology
    • Ophthalmic Imaging and Physiology
  • News News
  • ContactUs Contact Us

Preclinical Ophthalmic Contract Research

back-of-the-eye diseases

Pharma News: Bayer, Johns Hopkins partner to develop new ophthalmic therapies

June 23, 2015 //  by stanselb

Bayer HealthCare has entered into a five-year collaboration agreement with The Johns Hopkins University in Baltimore, US, for the discovery and development of new therapies in ophthalmology targeting retinal diseases.  Both the parties will jointly conduct research activities evaluating new targets and disease mechanisms, drug delivery technologies, and biomarkers for back-of-the-eye diseases with …

Category: NewsTag: Age-related macular degeneration, AMD, back-of-the-eye diseases, Diabetic Macular Edema, DME, drug delivery technologies, Ophthalmology, retinal disease

© 2021 · EyeCRO · All Rights Reserved.